BMS also have the first LAG-3 FDA approved product, now on the market - Relatlimab which is going well according to latest BMS annual report.
They could completely dominate the LAG-3 space overnight should they take efti into their stable.
I have flagged my opinions on this possibility previously and would like to see a BMS/Pfizer or Roche even, come to the party, to create the competitive tension needed.
Merck are in cruise control of Immutep and won't change unless there are other BP interested.
AIPAC 3 solo - is too little too late imo.
BMS also have the first LAG-3 FDA approved product, now on the...
-
- There are more pages in this discussion • 1,171 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |